The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis

Active, not recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions

Ulcerative Colitis

Trial Locations (1)

Child and Family Research Institute, Vancouver

All Listed Sponsors

lead

University of British Columbia

OTHER

NCT02721719 - The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis | Biotech Hunter | Biotech Hunter